Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil Sets Sights On Biogen’s Spinraza For First Risk Sharing Deal

Executive Summary

As Brazil turns to risk sharing agreements to improve access to expensive treatments, the health ministry has its eye on Biogen’s rare disease treatment Spinraza (nusinersen).

You may also be interested in...



Brazil Introduces New Measures To Tackle ‘Judicialization’ Of Access To Medicines

Brazil has announced new measures to try to deal with the costly problem of patients pursuing access to medicines through the courts.

Brazil’s Spiraling Access Suits And The Potential Impact On Companies

Spending on medicines as a result of litigation against health authorities is soaring in Brazil. Scrip investigates the challenges firms may face in future, including greater pricing pressure, a more NICE-like health technology appraisal system and increased scrutiny over any perceived industry wrongdoing.

Smaller EU Countries Call for More Comparative Trials

More should be done to incentivize comparative clinical trials so as to allow better decisions on drug pricing to be taken, said Austria’s representative at a recent meeting of EU health ministers.

Topics

Latest News
UsernamePublicRestriction

Register

PS124843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel